Tyra Biosciences (TYRA) Cash & Equivalents (2020 - 2026)

Tyra Biosciences has reported Cash & Equivalents for 7 years, with the latest figure at $85.0 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents fell 15.65% year-over-year to $85.0 million; the trailing twelve-month figure through Mar 2026 stood at $85.0 million (down 15.65% YoY), and the FY2025 full-year result was $77.4 million, down 15.85% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $85.0 million, up from $77.4 million in the prior quarter.
• The five-year high for Cash & Equivalents was $292.5 million in Q1 2022, with the low at $58.0 million in Q4 2023.
• Historically, Cash & Equivalents has averaged $164.9 million across 5 years, with a median of $103.9 million in 2024.
• Annual changes were most pronounced in 2022 — Cash & Equivalents soared 107.98% — and 2023, when it plunged 76.91%.
• Tyra Biosciences' Cash & Equivalents stood at $251.2 million in 2022, then sank by 76.91% to $58.0 million in 2023, then soared by 58.55% to $92.0 million in 2024, then decreased by 15.85% to $77.4 million in 2025, then increased by 9.78% to $85.0 million in 2026.
• The last three Cash & Equivalents figures came in at $85.0 million (Q1 2026), $77.4 million (Q4 2025), and $62.0 million (Q3 2025), per Business Quant data.